近5年全球在研心血管药物研发热点靶标及趋势分析  

Analysis on the hot spot targets and tendency of the global cardiovascular drug development in recent 5 years

作　　者：赵鸿萍[1] 蒋宏民[1] 相秉仁[1] 

机构地区：[1]中国药科大学信息管理与信息系统教研室,南京210009

出　　处：《中国药科大学学报》2012年第6期573-576,共4页Journal of China Pharmaceutical University

摘　　要：对Thomsonpharma检索获得的2008年1月至2012年3月全球在研的3 723个心血管药物进行统计分析,获得了近5年心血管药物研发的热点靶标、上市药物数量最多及上市药物比例最高的靶标、研发中止药物数量最多及研发中止药物比例最高的靶标,对部分心血管药物研发的趋势进行了预测。This paper apphes statistic analysis to the 3 723 cardiovascular drugs derived from the search of Thomsonpharma, which were developed during the period of January 1,2008 to March 20, 2012. The targets of the cardiovascular drugs for the past 5 years are obtaind as follows： the hot spots targets, the launched targets which are higest both in number and percentage and the discontined targets which are higest both in number and percentage. Furthermore, some developmental tendencies are revealed.

关 键 词：心血管药物 靶标 新药研发 趋势 

分 类 号：R96[医药卫生—药理学]